Association between hTERT polymorphisms and the risk of breast cancer in a sample of Southeast Iranian population

BMC Research Notes

Saeid Ghavami²  Mohsen Taheri¹  Seyed Mehdi Hashemi³  Mahboubeh Ebrahimi⁴  Shadi Amininia⁴  Mohammad Hashemi⁴ 

[1] Genetics of Non-communicable Disease Research Center, Zahedan University of Medical Sciences, Zahedan, Iran;Health Policy Research Centre, Shiraz Medical University, Shiraz, Iran;Department of Internal Medicine, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran;Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran

关键词: MNS16A;    Genotyping;    Polymorphism;    Breast cancer;    hTERT;   

Others  :  1092341
DOI  :  10.1186/1756-0500-7-895

 received in 2014-09-07, accepted in 2014-11-21,  发布年份 2014

【 摘 要 】

Background

Breast cancer (BC) is considered to be one of the most important causes of death worldwide, and it affects the Iranian female population a decade earlier than female in other parts of the world. Human telomerase reverse transcriptase (hTERT) is a main subunit of the telomerase complex. MNS16A is located downstream of the hTERT gene and is recognized as the regulator of hTERT promoter activity. The aim of the present study was to access the possible impact of hTERT variants on BC risk in an Iranian population in southeast Iran.

Methods

A total of 491 subjects including 266 BC patients and 225 healthy women participated in the study. Polymerase chain reaction (PCR) was used to genotype the MNS16A variable number of tandem repeats and 177 bp ins/del polymorphisms in the hTERT gene. PCR-RFLP and ARMS-PCR were used to genotype hTERT rs2736098 and 2735940, respectively. The association between genotypes and BC was assessed by computing the odds ratio (OR) and 95% confidence intervals (95% CI) from logistic regression analyses. A p-value of <0.05 was considered statistically significant.

Results

The MNS16A genotype frequency distribution in BC patients was: LL, 43.2%; LS, 51.1%; and SS, 5.7%, and in controls: LL, 29.5%; LS, 68.3%; and SS, 2.2%. The LS genotype decreased the risk of BC compared with LL (OR = 0.51, 95% CI = 0.35-0.75, p < 0.001). The hTERT 177 bp ins/del polymorphism was not polymorphic in our population. All subjects had the ins/ins genotype. Our findings indicate that the MNS16A genotype and hTERT rs2736098 variant were associated with BC risk in the study. We also showed that the rs2736098 A/G polymorphism increased the risk of BC (OR = 1.80, 95% CI = 1.12-2.88, p = 0.017, AG vs AA; OR = 1.80, 95% CI = 1.06-3.06, p = 0.033, GG vs AA; OR = 1.87, 95% CI = 1.19-2.94, p = 0.006, AG + GG vs AA). No significant association was found between the rs2735940 C/T variant and BC.

Conclusion

Our findings indicate that the MNS16A genotype and the hTERT rs2736098 variant influence the risk of BC in an Iranian population in southeast Iran.

【 授权许可】

   
2014 Hashemi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Youlden DR, Cramb SM, Dunn NA, Muller JM, Pyke CM, Baade PD: The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality. Cancer Epidemiol 2012, 36(3):237-248.
• [2]Wu JT, Kral JG: The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy. J Surg Res 2005, 123(1):158-169.
• [3]Turashvili G, Bouchal J, Burkadze G, Kolar Z: Differentiation of tumours of ductal and lobular origin: II. Genomics of invasive ductal and lobular breast carcinomas. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2005, 149(1):63-68.
• [4]Babu GR, Samari G, Cohen SP, Mahapatra T, Wahbe RM, Mermash S, Galal OM: Breast cancer screening among females in Iran and recommendations for improved practice: a review. Asian Pac J Cancer Prev 2011, 12(7):1647-1655.
• [5]Kolahdoozan S, Sadjadi A, Radmard AR, Khademi H: Five common cancers in Iran. Arch Iran Med 2010, 13(2):143-146.
• [6]Hashemi M, Fazaeli A, Ghavami S, Eskandari-Nasab E, Arbabi F, Mashhadi MA, Taheri M, Chaabane W, Jain MV, Los MJ: Functional polymorphisms of FAS and FASL gene and risk of breast cancer - pilot study of 134 cases. PLoS One 2013, 8(1):e53075.
• [7]Hashemi M, Eskandari-Nasab E, Fazaeli A, Taheri M, Rezaei H, Mashhadi M, Arbabi F, Kaykhaei MA, Jahantigh M, Bahari G: Association between polymorphisms of glutathione S-transferase genes (GSTM1, GSTP1 and GSTT1) and breast cancer risk in a sample Iranian population. Biomark Med 2012, 6(6):797-803.
• [8]Hashemi M, Eskandari-Nasab E, Fazaeli A, Rezaei H, Mashhadi MA, Arbabi F, Taheri M: Bi-directional PCR allele-specific amplification (bi-PASA) for detection of caspase-8–652 6 N ins/del promoter polymorphism (rs3834129) in breast cancer. Gene 2012, 505(1):176-179.
• [9]Amininia S, Hashemi M, Ebrahimi M, Mashhadi MA, Hashemi SM, Taheri M, Ghavami S: Association between CCNE1 polymorphisms and the risk of breast cancer in a sample of southeast Iranian population. Med Oncol 2014, 31(10):189.
• [10]Eskandari-Nasab E, Hashemi M, Ebrahimi M, Amininia S, Bahari G, Mashhadi MA, Taheri M: Evaluation of CCL5–403 G > A and CCR5 Delta32 gene polymorphisms in patients with breast cancer. Cancer Biomark 2014, 14(5):343-351.
• [11]Hashemi M, Omrani M, Eskanadri-Nasab E, Hasani SS, Mashhadi M, Taheri M: A 40-bp Insertion/Deletion Polymorphism of Murine Double Minute2 (MDM2) Increased the Risk of Breast Cancer in Zahedan, Southeast Iran. Iran Biomed J 2014, 18(4):245-249.
• [12]Basu N, Skinner HG, Litzelman K, Vanderboom R, Baichoo E, Boardman LA: Telomeres and telomere dynamics: relevance to cancers of the GI tract. Expert Rev Gastroenterol Hepatol 2013, 7(8):733-748.
• [13]Mason PJ, Perdigones N: Telomere biology and translational research. Transl Res 2013, 162(6):333-342.
• [14]Vodenicharov MD, Wellinger RJ: The cell division cycle puts up with unprotected telomeres: cell cycle regulated telomere uncapping as a means to achieve telomere homeostasis. Cell Cycle 2007, 6(10):1161-1167.
• [15]Qian Y, Yang L, Cao S: Telomeres and telomerase in T cells of tumor immunity. Cell Immunol 2014, 289(1–2):63-69.
• [16]Gomez DE, Armando RG, Farina HG, Menna PL, Cerrudo CS, Ghiringhelli PD, Alonso DF: Telomere structure and telomerase in health and disease (review). Int J Oncol 2012, 41(5):1561-1569.
• [17]Leem SH, Londono-Vallejo JA, Kim JH, Bui H, Tubacher E, Solomon G, Park JE, Horikawa I, Kouprina N, Barrett JC, Larionov V: The human telomerase gene: complete genomic sequence and analysis of tandem repeat polymorphisms in intronic regions. Oncogene 2002, 21(5):769-777.
• [18]Bacchetti S, Counter C: Telomeres and telomerase in human cancer (review). Int J Oncol 1995, 7(3):423-432.
• [19]Meyerson M: Role of telomerase in normal and cancer cells. J Clin Oncol 2000, 18(13):2626-2634.
• [20]O'Sullivan RJ, Karlseder J: Telomeres: protecting chromosomes against genome instability. Nat Rev Mol Cell Biol 2010, 11(3):171-181.
• [21]Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100(1):57-70.
• [22]Wang L, Soria JC, Chang YS, Lee HY, Wei Q, Mao L: Association of a functional tandem repeats in the downstream of human telomerase gene and lung cancer. Oncogene 2003, 22(46):7123-7129.
• [23]Andersson U, Osterman P, Sjostrom S, Johansen C, Henriksson R, Brannstrom T, Broholm H, Christensen HC, Ahlbom A, Auvinen A, Feychting M, Lönn S, Kiuru A, Swerdlow A, Schoemaker M, Roos G, Malmer B: MNS16A minisatellite genotypes in relation to risk of glioma and meningioma and to glioblastoma outcome. Int J Cancer 2009, 125(4):968-972.
• [24]Jin G, Yoo SS, Cho S, Jeon HS, Lee WK, Kang HG, Choi YY, Choi JE, Cha SI, Lee EB, Kim CH, Jung TH, Kim YT, Park JY: Dual roles of a variable number of tandem repeat polymorphism in the TERT gene in lung cancer. Cancer Sci 2011, 102(1):144-149.
• [25]Wang Y, Hu Z, Liang J, Wang Z, Tang J, Wang S, Wang X, Qin J, Wang X, Shen H: A tandem repeat of human telomerase reverse transcriptase (hTERT) and risk of breast cancer development and metastasis in Chinese women. Carcinogenesis 2008, 29(6):1197-1201.
• [26]Hofer P, Baierl A, Feik E, Fuhrlinger G, Leeb G, Mach K, Holzmann K, Micksche M, Gsur A: MNS16A tandem repeats minisatellite of human telomerase gene: a risk factor for colorectal cancer. Carcinogenesis 2011, 32(6):866-871.
• [27]Hashemi M, Eskandari-Nasab E, Fazaeli A, Bahari A, Hashemzehi NA, Shafieipour S, Taheri M, Moazeni-Roodi A, Zakeri Z, Bakhshipour A, Ghavami S: Association of genetic polymorphisms of glutathione-S-transferase genes (GSTT1, GSTM1, and GSTP1) and susceptibility to nonalcoholic fatty liver disease in Zahedan, Southeast Iran. DNA Cell Biol 2012, 31(5):672-677.
• [28]Sole X, Guino E, Valls J, Iniesta R, Moreno V: SNPStats: a web tool for the analysis of association studies. Bioinformatics 2006, 22(15):1928-1929.
• [29]Hashemi M, Eskandari-Nasab E, Moazeni-Roodi A, Naderi M, Sharifi-Mood B, Taheri M: Association of CTSZ rs34069356 and MC3R rs6127698 gene polymorphisms with pulmonary tuberculosis. Int J Tuberc Lung Dis 2013, 17(9):1224-1228.
• [30]Hoch NC, Lai X, Heierhorst J: Genomic stability disorders: from budding yeast to humans. Front Biosci 2013, 5:396-411.
• [31]Xia X, Rui R, Quan S, Zhong R, Zou L, Lou J, Lu X, Ke J, Zhang T, Zhang Y, Liu L, Yan J, Miao X: MNS16A tandem repeats minisatellite of human telomerase gene and cancer risk: a meta-analysis. PLoS One 2013, 8(8):e73367.
• [32]Zagouri F, Sergentanis TN, Gazouli M, Tsigginou A, Dimitrakakis C, Eleutherakis-Papaiakovou E, Papaspyrou I, Chrysikos D, Theodoropoulos G, Zografos GC, Antsaklis A, Dimopoulos AM, Papadimitriou CA: HTERT MNS16A polymorphism in breast cancer: a case-control study. Mol Biol Rep 2012, 39(12):10859-10863.
• [33]Wang L, Wei Q, Wang LE, Aldape KD, Cao Y, Okcu MF, Hess KR, El-Zein R, Gilbert MR, Woo SY, Prabhu SS, Fuller GN, Bondy ML: Survival prediction in patients with glioblastoma multiforme by human telomerase genetic variation. J Clin Oncol 2006, 24(10):1627-1632.
• [34]Carpentier C, Lejeune J, Gros F, Everhard S, Marie Y, Kaloshi G, Laigle-Donadey F, Hoang-Xuan K, Delattre JY, Sanson M: Association of telomerase gene hTERT polymorphism and malignant gliomas. J Neurooncol 2007, 84(3):249-253.
• [35]Savage SA, Chanock SJ, Lissowska J, Brinton LA, Richesson D, Peplonska B, Bardin-Mikolajczak A, Zatonski W, Szeszenia-Dabrowska N, Garcia-Closas M: Genetic variation in five genes important in telomere biology and risk for breast cancer. Br J Cancer 2007, 97(6):832-836.
• [36]Mocellin S, Verdi D, Pooley KA, Landi MT, Egan KM, Baird DM, Prescott J, De Vivo I, Nitti D: Telomerase reverse transcriptase locus polymorphisms and cancer risk: a field synopsis and meta-analysis. J Natl Cancer Inst 2012, 104(11):840-854.
• [37]Haiman CA, Chen GK, Vachon CM, Canzian F, Dunning A, Millikan RC, Wang X, Ademuyiwa F, Ahmed S, Ambrosone CB, Baglietto L, Balleine R, Bandera EV, Beckmann MW, Berg CD, Bernstein L, Blomqvist C, Blot WJ, Brauch H, Buring JE, Carey LA, Carpenter JE, Chang-Claude J, Chanock SJ, Chasman DI, Clarke CL, Cox A, Cross SS, Deming SL, Diasio RB, et al.: A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet 2011, 43(12):1210-1214.
• [38]Burke LS, Hyland PL, Pfeiffer RM, Prescott J, Wheeler W, Mirabello L, Savage SA, Burdette L, Yeager M, Chanock S, De Vivo I, Tucker MA, Goldstein AM, Yang XR: Telomere length and the risk of cutaneous malignant melanoma in melanoma-prone families with and without CDKN2A mutations. PLoS One 2013, 8(8):e71121.
• [39]Pellatt AJ, Wolff RK, Torres-Mejia G, John EM, Herrick JS, Lundgreen A, Baumgartner KB, Giuliano AR, Hines LM, Fejerman L, Cawthon R, Slattery ML: Telomere length, telomere-related genes, and breast cancer risk: the breast cancer health disparities study. Genes Chromosomes Cancer 2013, 52(7):595-609.